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Resumo 
 
O carcinoma de células renais (CCR) é a neoplasia renal mais frequentemente 
diagnosticada no adulto (cerca de 90% dos casos) e é também considerada a neoplasia 
urológica mais letal. Esta neoplasia é responsável por mais de 100 000 mortes por ano a 
nível mundial, observando-se também um aumento das taxas de incidência e mortalidade 
(2-3% por década). A inexistência de um teste de screening para a deteção precoce e 
follow-up contribuí para o facto de 1/3 dos doentes serem diagnosticados com doença 
metastática e cerca de 20-40% do doentes submetidos a cirurgia desenvolverem 
metástases. A hipótese da existência de uma comunicação celular dependente de 
exossomas tem vindo a revolucionar a biologia molecular, criando espaço para a 
reformulação da hipótese que suporta o envolvimento do microambiente tumoral como 
indutor/modulador do processo metastático. Dos vários tipos de ácidos nucleicos capazes 
de serem transportados pelos exossomas, são de destacar os microRNAs (miRNAs). Os 
miRNAs são pequenas moléculas de RNA não codificante responsáveis pela regulação 
pós-transcricional de inúmeros genes e têm sido amplamente estudados em Oncologia 
uma vez que estão desregulados no cancro, podendo influenciar o desenvolvimento 
neoplásico. 
O objetivo do presente estudo foi o estabelecimento de um perfil de expressão de 
miRNAs em circulação que possa ser utilizado como biomarcador de diagnóstico e/ou 
prognóstico em doentes com CCR. Para tal foi realizado um estudo in vitro em linhas 
celulares de rim, uma normal e uma metastática (HK-C8 e FG-2, respetivamente), a fim 
de estabelecer um perfil de miRNAs desregulados em CCR. Numa segunda fase, o perfil 
de miRNAs obtido foi validado em amostras de plasma de doentes com CCR (n = 50) e 
em indivíduos saudáveis (n = 50), assim como foi analisado o seu impacto na 
sobrevivência global dos doentes com CCR. 
Dos 5 miRNAs estudados nas linhas celulares, apenas o miR-210, o miR-218 e o 
miR-1233 apresentaram níveis de excreção mais elevados na linha FG-2 (miR-210: fold-
increase = 2.64, P=0.020; miR-218: fold-increase = 302, P=0.002; miR-1233: fold-
increase = 10.63, P=0.021). Quando analisámos os níveis de expressão destes miRNAs 
na população, observamos que o miR-210, miR-218 e miR-1233 apresentavam níveis de 
expressão aumentados nas amostras de plasma dos doentes com CCR 
comparativamente aos indivíduos saudáveis (miR-210: fold-increase = 5.24, P≤0.001; 
miR-218: fold-increase = 27.10, P≤0.001; miR-1233: fold-increase = 52.34, P≤0.001). 
Observámos também que o aumento dos níveis de expressão destes miRNAs se 
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encontrava associados a características clinicopatológicas, nomeadamente: tamanho 
tumoral superior (miR-210: fold-increase = 7.84, P≤0.001; miR-1233: fold-increase = 8.05, 
P=0.007), maior grau de Fuhrman (miR-1233: fold-increase = 5.13, P=0.011), presença 
microinvasão vascular (miR-210: 3.97 fold-increase, P=0.049; miR-1233: fold-increase = 
8.40, P=0.012) e presença de metástases no momento do diagnóstico (miR-210: fold-
increase = 4.63, P=0.005; miR-218: fold-increase = 16.68, P=0.014; miR-1233: fold-
increase = 5.43, P=0.032). Adicionalmente, observámos também que, doentes que 
expressam níveis elevados de miR-210 e miR-1233 em circulação, apresentam uma 
sobrevivência global menor (Log Rank test, P = 0.036).  
A hipóxia é um evento primário no CCR, devido à alteração do gene VHL, e é 
responsável pela indução da angiogénese e vascularização necessárias ao 
desenvolvimento tumoral. Tanto o miR-210 como o miR-1233 são induzidos pela hipóxia 
e parecem atuar sinérgicamente para manter a resposta ao estado de hipóxia por parte 
da célula, uma vez que levam à sobreexpressão de genes relacionados com a 
proliferação, angiogénese, metastização e inibição da apoptose, o que se traduz num pior 
prognóstico e numa menor sobrevivência global. 
Deste modo, e com base nos resultados obtidos, podemos concluir que o miR-210 
e o miR-1233 são bons candidatos a biomarcadores de prognóstico e agressividade em 
CCR. 
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Abstract 
 
Renal cell carcinoma (RCC) is the most common solid cancer of the adult kidney, 
accounting for approximately 90% of kidney neoplasms and 3% of all adult malignancies. 
Worldwide mortality as a result of RCC currently exceeds 100.000 patients each year, 
with the incidence and mortality rate increasing by 2-3% per decade. This reality and the 
nonexistence of a standard screening test, contributes to the fact that one-third of patients 
are diagnosed with local invasive disease or metastatic disease. Moreover 20-40% of 
RCC patient’s submitted to surgical nephrectomy will also develop metastasis. The 
hypothesis of exossome-dependent signaling between cells has been revolutionizing 
molecular biology and giving space for reformulating the hypothesis of tumor 
microenvironment as modulator of the metastatic process. Among the cargo that can be 
transported through exosomes we can find microRNAs (miRNAs). miRNAs are small non-
coding RNAs that are responsible for the regulation of numerous genes at a post-
transcriptional level. MiRNAs have been widely studied in oncology since they have been 
proved to be deregulated in cancer and also have influence in cancer development. 
The aim of this study was the establishment of a circulating miRNA expression 
profile that could be used as a biomarker of diagnosis and/or prognosis in RCC patients. 
In order to do that we first performed an in vitro study using renal cell lines, one normal 
and the other metastatic (HK-C8 and FG-2, respectively), to establish a profile of 
deregulated miRNAs in RCC. In a second phase, we validated the miRNA profile obtained 
in plasma samples of RCC patients (n = 50) and healthy individuals (n = 50), and also 
evaluated its impact in the patients overall survival. 
From the 5 miRNAs studied in the cell lines, only miR-210, miR-218 and miR-1233 
presented higher circulating expression levels in the FG-2 cell line (miR-210: fold-increase 
= 2.64, P=0.020; miR-218: fold-increase = 302, P=0.002; miR-1233: fold-increase = 10.63, 
P=0.021). When we analyzed the expression levels of these miRNAs in the population, we 
observed that miR-210, miR-218 and miR-1233 presented higher expression levels in 
plasma samples of RCC patients compared to healthy individuals (miR-210: fold-increase 
= 5.24, P≤0.001; miR-218: fold-increase = 27.10, P≤0.001; miR-1233: fold-increase = 
52.34, P≤0.001). We also observed that the increase of the expression levels of these 
miRNAs were associated with clinicopathological characteristics, namely: higher tumor 
size (miR-210: fold-increase = 7.84, P≤0.001; miR-1233: fold-increase = 8.05, P=0.007), 
higher Fuhrman nuclear grade (miR-1233: fold-increase = 5.13, P=0.011),  microvascular 
invasion (miR-210: 3.97 fold-increase, P=0.049; miR-1233: fold-increase = 8.40, P=0.012) 
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and presence of metastasis at the time of diagnosis (miR-210: fold-increase = 4.63, 
P=0.005; miR-218: fold-increase = 16.68, P=0.014; miR-1233: fold-increase = 5.43, 
P=0.032). Additionally, we observed that patients that had higher expression levels of 
both miR-210 and miR-1233 presented a lower overall survival (Log Rank test, P = 0.036).  
Hypoxia is a primary event in RCC, due to the loss or mutation of VHL gene, and is 
a well-established inducer of angiogenesis and vascularization, necessary for further 
tumor development. Both miR-210 and miR-1233 are induced by hypoxia and they appear 
to act synergically in order to maintain the hypoxic response from the cell since they lead 
to the overexpression of genes related to proliferation, angiogenesis, metastization and 
inhibition of apoptosis, which culminates in a poor prognosis and a lower overall survival. 
Thus, based on these results, we conclude that miR-210 and miR-1233 are good 
candidates for biomarkers of prognosis and aggressiveness in RCC. 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
1. Introduction 
 
 
Circulating microRNAs and Renal Cell Carcinoma 
25 
1. Introduction 
 
1.1. Cancer: general concepts 
Cancer has revealed itself as an emergent public health problem worldwide. 
Nowadays it represents the first and the third cause of death in the developed countries  
and in the less developed countries, respectively [1]. According to GLOBOCAN 2012, the 
International Agency for Research on Cancer (IARC) online database, an estimated 14.1 
million new cancer cases and 8.2 million cancer-related deaths occurred in 2012, 
compared with 12.7 million and 7.6 million, respectively, registered in 2008 [2]. Estimates 
prevalence rates for 2012 show that there were 32.6 million people (over the age of 15 
years) alive who had had a cancer diagnosed in the previous five years [3]. Projection 
based on the GLOBOCAN 2012 estimates predicts a substantive increase to 19.3 million 
new cases per year by 2025, due to growth and ageing of the global population [2]. 
Despite the achievements in the field of Oncology, whether in the early detection of 
some neoplasias or in the development of new treatments more effective in disease 
management, the upcoming of resistance to these treatments has become a difficult 
obstacle to overcome. Cancer is a heterogeneous disease, with different etiology 
and natural history that develops trough the interactions between environmental 
and genetic factors, involving deregulation of multiple pathways responsible for the 
fundamental cell processes, such as death, proliferation, differentiation and cell 
migration [4].  
In the beginning of the process of carcinogenesis the cell must undergo a change, 
genetic and / or epigenetic, which may lead to changes in gene activity through 
chromosomal rearrangements and translocations, deletions, insertions, amplification of 
certain genes and point mutations, giving the cell the potential to become a neoplastic [5]. 
Subsequently, multiple events occurs that result in the disruption of key cellular processes 
such as cell proliferation and apoptosis, which in turn lead to the growth and development 
of malignancies. The mutations acquired during neoplastic development make the cells 
less sensitive to apoptotic signals, cell growth stop and destruction by the immune 
system. Cumulatively, the self-sufficiency of these cells in growth factors provides them 
with greater proliferative capacity, angiogenesis and invasive potential. These factors 
combined with increase in inflammation, genomic instability and cell energy deregulation, 
favor cancer development and systemic dissemination, enhancing the metastatic process 
[6, 7]. 
However, despite the existing knowledge of several genetic factors on tumor 
pathophysiology, understanding the complex molecular mechanisms underlying its 
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Figure 1 - The tumor microenvironment. (Adapted from Joyce et al. 2009 [9]). 
development remains incomplete, implying that besides the intrinsic malignant properties 
of tumor epithelial cells, other factors such as microenvironmental changes may  modulate 
progression, invasion and metastasis [8]. 
Over the past decade, tumors have increasingly been recognized as organs whose 
complexity approaches and may even exceed that of normal healthy tissues. When 
analyzed from this point of view, the biology of a tumor can only be understood by 
studying the individual specialized cell types within it as well as the “tumor 
microenvironment” that they construct during the course of tumorigenisis. This approach 
contrasts with the earlier view of a tumor as nothing more than a cluster of transformed 
cells standing alone, whose entire biology could be understood by elucidating their cell-
autonomous properties. 
Cancer cells in primary tumors are surrounded by a complex microenvironment. 
This microenvironment is composed by numerous types of cells including endothelial cells 
of the blood and lymphatic circulation, stromal fibroblasts and a variety of bone-marrow-
derived cells including macrophages, myeloid-derived suppressor cells, TIE-2 expressing 
monocytes and mesenchymal stem cells (Figure 1) [9]. 
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Environmental alterations, together with natural viability in hereditary traits, 
continuously shape species. The tumorigenic process shares many similarities with the 
evolution of ecosystems; within tumors, a continuous selection exists for tumor cells with 
the highest survival and proliferative advantage. Moreover, tumors persistently shape their 
microenvironment, thereby establishing an abnormal ecosystem surrounding them [10]. 
Mathematical modeling studies, combined with experimental data, suggests that 
microenvironmental conditions, such as hypoxia and heterogeneous extracellular matrix, 
provide selective pressure for tumor evolution and progression to invasion phenotypes 
[11, 12].  
One way of microenvironment shaping is through paracrine and/or systemic 
signaling between cells. This type of intercellular communication is made through 
exchange of biomolecules between cells and it’s essential for functional integrity of 
multicellular organisms. Shed extracellular membrane vesicles (EMVs) serve to shuttle 
bioactive molecules between cells, and their cargo can modulate the extracellular 
environment [13]. The best characterized EMVs are the exossomes, 50- to 100-nm 
vesicles generated intracellularly in multivesicular bodies (MVBs) and released upon 
MVBs with the plasma membrane [13, 14].  
Exossome-mediated cell communication includes, but is not restricted to, direct 
activation of cell-surface receptors on recipient cells, transfer and translation of mRNAs, 
transfer of microRNAS (miRNAs) and silencing of mRNA targets, transfer of functional 
proteins and the induction of cell signaling pathways upon their internalization and also 
genomic DNA and cDNA [13, 15]. Thus, exosomes can select bioactive molecules and 
propagate the horizontal transfer of their cargo and, consequently, have an enormous 
impact on tumor growth, survival and spread, along with demonstrated effects on many 
stages of tumor progression, angiogenesis, escape from immune surveillance, 
extracellular matrix degradation and metastasis [14, 16, 17]. Since  they are released into 
the circulation, exosome-dependent signaling may occur not only locally, but also in a 
paracrine and systemic manner, which can have a direct impact in tumor progression and 
in metastization process (Figure 2)  [15]. 
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Figure 2 - Schematic model of exossome secretion in cancer cells. Exossome membranes are enriched in 
cholesterol, sphingomyelin, and ceramide, as well as lipid raft associated proteins. These components allow 
exosomes to be highly stable in numerous body fluids. Exosomes released from cancer cells can be taken up by 
neighboring cells and are capable of inducing pathways involved in cancer initiation and progression [14]. 
 
 
 
Given that this area is still underexplored, elucidating the nature of tumor cell 
interactions and the mechanisms of co-evolution of tumor cells and their 
microenvironment it’s crucial for our understanding of what drives tumor initiation and 
progression and for the development of better cancer preventative and therapeutic 
interventions. 
 
 
1.2. Renal Cell Carcinoma 
Renal cell carcinoma (RCC) is the most common solid cancer of the adult kidney, 
accounting for approximately 90% of kidney neoplasms and 3% of all adult malignancies 
[18, 19]. According to the European Association of Urology (EAU), there is a 1.5:1 
predominance of new cases diagnosed in men over women, with a peak incidence 
occurring between the age of 60 and 70 years [19]. Worldwide mortality as a result of 
RCC currently exceeds 100.000 patients each year, with the incidence and mortality rate 
increasing by 2-3% per decade [20]. 
Incidence and mortality rates of RCC also show a geographic variation: the highest   
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Figure 3 - Distribution of incidence and mortality rates of kidney cancer by 100 000 habitants 
(Globocan 2012, IARC). 
incidence rates are observed in Northern America, Western Europe and Australia, 
whereas the lowest are observed in India, China and Africa. The highest mortality rates 
are registered in the European continent, mainly in the Central and Eastern countries, 
followed by the western and southern regions (Figure 3) [21]. In 2008, the number of new 
cases diagnosed in the European Union was 88 400 and the number of kidney cancer-
related deaths was 39 300 [22].The geographic disparity observed in RCC incidence rates 
worldwide can be attributed to differences in diagnosis frequency, access to health care, 
genetic inheritance and prevalence of certain lifestyle habits and/or environmental risk 
factors [23].  
 
 
 
 
 
 
 
 
 
 
The exact causes of RCC aren’t completely identified but epidemiologic studies 
reveal that certain lifestyle habits seem to be involved in the etiology and development of 
this disease. Smoking habits, obesity, acquired cystic disease and family history of RCC 
are well established as risk factors [24, 25]. However, there are others, like nutritional 
factors, hypertension and occupational exposure, that also seem to modulate the 
development of RCC but further studies are necessary to clarify their association with the 
disease [26]. 
 
1. Introduction 
 
 
Circulating microRNAs and Renal Cell Carcinoma 
30 
 
Currently, most RCCs are detected accidentally as a consequence of imaging 
examinations, such as computed tomography and magnetic resonance imaging, mostly 
due to symptoms that are not specifically related to RCC [27]. An explanation for this fact 
is that many renal masses remain asymptomatic and non-palpable until the late stages of 
the disease [18, 19]. In these cases the prognosis is good and further exams, such as 
biopsies and aspiration cytology, are needed to confirm the tumor neoplastic nature. 
Clinical symptoms, such as flank pain, gross heamaturia, palpable abdominal mass, and 
paraneoplastic syndromes, only appear when the tumor presents a larger diameter, which 
indicates a worse prognosis [19, 28-30]. This reality and the nonexistence of a standard 
screening test, contributes to the fact that one-third of patients are diagnosed with local 
invasive disease or metastatic disease [27]. For patients with clinically localized disease, 
the 5-year survival rates range from 90.4% for patients with organ-confined disease to 
61.7% for patients with regional spread [31]. Regarding the patients that are diagnosed 
with organ confined disease, 20-40% will also develop metastasis [27]. In patients with 
distant metastases, the 5-year survival is 9.5% [31]. 
According to the World Health Organization (WHO), the three major histologic 
subtypes of RCC are: clear cell (80-90%), papillary (10-15%) and chromophobe (4-5%) 
and the most aggressive is the clear cell Renal Cell Carcinoma (ccRCC) subtype [32]. 
Histologic factors influencing prognosis include Fuhrman grade, histologic subtype, 
presence of sarcomatoide features, microvascular invasion, tumor necrosis, and collecting 
system invasion. Although it is subject to intraobserver and interobserver discrepancies, 
the Fuhrman nuclear grade is the most widely accepted histologic grading system for 
RCC [32]. This classification system groups the neoplasias in four grades of 
aggressiveness, by evaluating the size and characteristics of the cells nucleous (Table I). 
 
 
 Nuclear diameter Nuclear Shape Nucleoli 
Grade I 10 µm Round, uniforme Non-visible 
Grade II 15 µm 
Some irregularities in 
outline 
Visible at  high 
magnification (400X) 
Grade III 20 µm 
Obvious irregularities 
in outline 
Visible at low 
magnification (100X) 
Grade IV As Grade III 
Bizarre, multi-lobed, 
with cromatin clumps 
Visible at low 
magnification (100X) 
Table I – Fuhrman nuclear grade classification. 
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Surgical intervention is the primary treatment for the treatment of RCC detected at 
early stage. However, surgery alone has a limited benefit in patients with metastatic 
disease, except for palliative reasons [20, 33]. Until the past decade, the treatment options 
for patients with metastatic RCC (mRCC) have been extremely limited, as RCC is 
notoriously resistant to cytotoxic chemotherapy and radiotherapy [34, 35]. Prior to the use 
of antiangiogenic agents, systemic treatment options for mRCC were limited to cytokine 
therapies (interleukin [IL]-2 and interferon-alpha [IFN-α]) but they were proved to be 
ineffective since only a small percentage of the patients showed benefit in long term 
disease-free survival [36, 37]. In the past years, following the elucidation of various 
molecular pathways in RCC, targeted agents such as receptor tyrosine kinase inhibitors 
(TKIs), vascular endothelial growth factor (VEGF) antibodies, and mammalian target of 
rampamycin inhibitors (mTORs) are now a crucial part of most therapeutic strategies for 
patients with mRCC [27, 33, 38]. Although the outcome of the patients has improved, 
many tumors develop resistance to targeted therapies due compensatory change within 
the target pathway that bypass the site of inhibition [39, 40]. 
 
 
 
1.2.1. Molecular biology of RCC 
As previously said, the three major types of RCC are clear cell (80-90%), papillary 
(10-15%) and chromophobe (4-5%) [32]. Both the clear cell and the papillary type can be 
sporadic or caused by inherited syndromes (Figure 4), while the chromophobe type is only 
caused by an inherited syndrome called Birt-Hogg-Dubé syndrome. This syndrome is a 
rare autosomal dominant disorder characterized by hair follicle hamartomas 
(fibrofofolliculomas) of the face and neck, and about 15% of the affected patients have 
multiple renal tumors (Figure 4) [41, 42].  
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Figure 4 - Steps in the Development of Renal Cell Carcinoma. In contrast to sporadic renal cell 
carcinoma (A and C), fewer steps are required for the development of RCC in the inherited forms of 
the disease (B e D), because all of the patient’s cells have a mutation that predisposes the patient to 
the disease. As a result, the disease associated with the familial syndromes occurs earlier and its 
often multifocal. Each familiar renal cancer syndrome is autosomal dominant. In von Hippel-Lindau 
(VHL) disease, a cellular recessive mechanism is involved, since both copies of the VHL gene are 
inactivated (A and B). VHL is a classic tumor suppressor gene. In hereditary papillary renal carcinoma, 
one copy of the MET gene has an activating mutation, which is inherited (D). Chromosome 7, which 
includes the defective MET allele, becomes duplicated, increasing the level of expression of the 
activated MET protein, which is as receptor tyrosine kinase for hepatocyte growth factor. Activated 
MET is a classic oncogene. The (+) represents the wild-type allele; (-) represents a null allele. A (+) in 
red represents a mutated, activated allele; (+ +) in red represent duplication of that allele. (Adapted 
from Cohen et al. 2005 [35]). 
 
 
Despite intensive efforts, the molecular mechanisms involved in ccRCC 
development and progression remain not completely understood. One of the established 
signaling pathways involved in the pathophysiology of RCC is the von Hippel-Lindau 
(VHL) pathway [43-46]. In normoxic conditions, the protein encoded by the VHL gene 
serves as a recognition site for the regulatory subunits of HIF, targeting them to the 
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Figure 5 - Signaling pathways involved in renal cell carcinoma pathophysiology. (A) pVHL pathway under 
normoxic conditions: pVHL targets HIF-α for degradation in the proteasome.(B) pVHL pathway under hypoxic 
conditions: the loss of VHL leads to the accumulation of HIF-α in the nucleous and consequene binding to 
transcription factors, which triggers a hypoxic response from the cell. (C) EGFR pathway activation by TGF-α 
and its consequences. (Adapted from Dias et al. 2013 [49]). 
proteasome degradation (Figure 5 (A)). One of the early molecular events of RCC is the 
loss of pVHL (a consequence of the loss of the short arm of chromosome 3), which stops 
the degradation of HIF and leads to its accumulation in the cytoplasm and further 
migration to the nucleus where it binds to hypoxia-related genes, leading to a hypoxic 
response from the cell in non-hypoxic conditions. Once activated, these genes are 
involved in pathways responsible for the development of blood vessels, proliferation, 
glucose metabolism, pH regulation and metastatic disease (Figure 5B) [46-49]. 
One of the activated genes is Transforming Growth Factor α (TGF-α), which is 
involved in the induction of cellular proliferation by activating the Epidermal Growth Factor 
Receptor (EGFR) [50]. The EGFR activates several signaling pathways such as 
MAPK/ERK and PI3K/AKT which in turn modulate genetic transcription, stimulating 
cellular proliferation, migration, invasion, angiogenesis and apoptosis (Figure 5C)[51].  
 
 
EGFR is a well known tyrosine kinase receptor often deregulated in cancer. This 
receptor is overexpressed in, approximately, 30% of primary tumors of several cancer 
types and has been associated with advanced disease, poor prognosis, limited overall 
survival and therapy response[52, 53].The VHL is also responsible for EGFR turnover and 
further degradation in the proteosome, thus during the RCC development this process 
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could be compromised leading to an increase of EGFR [54]. Zhou and co-workers 
described EGFR half-life as approximately 1 hour in 786-VHL cells but approximately 3 
hours in 786-mock cells and that both phospo-AKT and the phospo-ERK signals lasted 
longer in 786-mock cells than in 786-VHL cells when stimulated with Epidermal Growth 
Factor (EGF) [54]. It as also been described that hypoxia upregulates EGFR and prolongs 
its activation through its retention in endocytic trafficking [24]. Recently, Shen and 
colleagues demonstrated that EGFR is upregulated during tumor progression and 
specifically enriched in hypoxic tumor areas. They also desmonstrate that EGFR 
suppresses the maturation of specific tumour-suppressor-like miRNAs in response to 
hypoxic stress through phosphorylation of argonaute 2 (AGO2) at Tyrosine 393 [55].  
If we relate the VHL loss with the consequent increase in EGFR half-life (which is 
also upregulated by the hypoxic conditions) and TGF-α production, it becomes clear the 
relevance of studying this pathway to further understanding of ccRCC molecular biology, 
and the involvement of this pathway in ccRCC tumor progression.  
In recent years, the increasing knowledge of the pathways involved in ccRCC has 
allowed the development of new targeted therapies. The identification of alterations in 
VHL gene in ccRCC led to the development of targeted therapies such as sunitinib and 
sorafenib (tyrosine kinase inhibitors) as well as pazopanib (angiogenesis inhibitor) [46, 
56]. However, a subset of patients (~25%) do not seem to experience any clinical benefit 
from these targeted therapies, while in the majority of cases, patients respond to therapy 
initially but later develop resistance to it and enter in the phase of disease progression 
[39]. Usually, resistance to the targeted agents in ccRCC patients has been shown to 
develop after a median of 5-11 months of treatment and a small subset of patients do not 
experience any clinical benefit from the targeted therapy [40]. These “failures” of targeted 
therapies show us the necessity of further investigation into the molecular pathways 
involved in RCC in order to improve our understanding about the molecular events in this 
type of cancer and to allow for the development of new effective targets and therapies. 
Another issue related to RCC is the absence of accurate biomarkers for disease 
diagnosis, follow-up and monitoring treatment response.  
Currently, no standard approaches to biomarker sampling or analysis have been 
adopted for RCC since many of the putative tumor markers themselves are still under 
active investigation for further validation [57]. The ideal biomarker must be accessible 
using non-invasive protocols, inexpensive to quantify, specific to the disease of interest, a 
reliable early indication of disease before clinical symptoms appear and a way to stratify 
the disease and assess response to therapy [58]. The establishment of a biomarker isn’t 
an easy task since possible biomarkers in body fluids are susceptible to degradation by 
circulating proteases and nucleases, thereby decreasing their signal, and on the other 
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hand, endogenous production of biomarker molecules by normal cells may artificially 
augment the signals [59, 60].   
Urine metabolomics analysis is theoretically promising but difficulties with the 
heterogeneous nature of urine metabolites, potential contamination of nonhuman 
metabolites from genitourinary flora, and special handling requirements have limited the 
progress of using it as a source of biomarkers in RCC [61]. Although many groups have 
studied biomarkers for diagnosis, prognosis and prediction of therapy response in RCC, 
these efforts have unfortunately been preliminary and uncoordinated. The majority of the 
studies were limited by small, retrospective, convenience cohorts that have not been 
replicated by independent groups while others have been validated with small test subsets 
and performed well, but they also lack external validation with larger cohorts [57]. 
From all the possible biomarkers that were studied in RCC, the ones that can fit all 
the categories (diagnosis, prognosis and predictive of response) were the miRNAs, but as 
the rest, further research is needed in order to validate them [62-66]. 
 
 
1.3. MicroRNAs 
MiRNAs are a family of small non-coding RNAs (19-25 nucleotides in length) that 
regulate gene expression by sequence-selective targeting of mRNAs, leading to their 
degradation or blockade at the post-transcriptional level, depending on the degree of 
complementarity between miRNAs and the target mRNA sequence [67, 68]. For the 
majority of miRNAs, the primary transcripts are generated in the nucleus [69]. Following 
transcription, the pre-miRNA is processed by DROSHA and its binding partner DGCR8 
(also known as Pasha), creating a pre-miRNA [70]. The pre-miRNAs are exported to the 
cytoplasm by the nuclear export protein XPO5, where they are further processed by 
DICER, leading to the production of mature 22 nucleotide-stranded molecules [71]. The 
mature miRNA enters the RISC complex where it becomes a single-stranded functional 
miRNA. This single-stranded miRNA then induces post-transcriptional gene silencing by 
guiding the RISC complex to target miRNAs. Target recognition occurs mainly by 
incomplete base pairing complementarity between the miRNA and the target mRNA 
resulting in mismatches that, in turn, lead to target gene silencing, which can occur via 
translational repressing or mRNA degradation (Figure 6) [71, 72]. 
MiRNA expression is dynamic, since it is postulated that each miRNA regulates up 
to 100 different mRNAs and that more than 10.000 mRNAs appear to be directly regulated 
by miRNAs [73]. This variability makes miRNAs potent modulators of cellular behavior, 
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Figure 6 - MiRNA biogenesis and function (adapted from Dias et al. 2013 [49]). 
since several miRNAs can target the same gene and one single miRNA can target 
multiple genes [74]. As a single miRNA may target up to several hundred mRNAs, 
aberrant miRNA expression may affect a multitude of transcripts and profoundly influence 
cancer-related signaling pathways [69]. Hence, miRNAs have been identified as key 
regulators in many biological processes including cell development, differentiation, 
apoptosis and proliferation [75]. Many miRNAs have been identified to act as oncogenes, 
tumor suppressors or even modulators of cancer stem cells and metastasis formation [76]. 
OncomiRs are known to downregulate tumor suppressor genes, and have been reported 
to be overexpressed in multiple miRNA-profiling studies. On the other hand, tumor 
suppressor miRNAs are responsible for downregulating oncogenes, and are mostly 
underexpressed in cancer [33]. 
 
 
 
 
One of the most important features of miRNAs is that they have different 
expression patterns in normal cells when compared with cancer cells, which makes them 
excellent candidates for biomarkers [77].  In addition to that, miRNA expression signatures 
in blood, serum and plasma are similar between species, as well in individuals of different 
ages [58]. On the other hand, levels of miRNAs in circulating samples are reproducible 
and consistent among individuals from the same species and specific expression patterns 
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of serum miRNAs have already been identified for pregnancy, diabetes, and different 
cancers, thus providing evidence that plasma miRNAs contain fingerprints distinctive of 
certain human conditions [19]. Circulating miRNAs are also stable after being submitted to 
severe conditions, such as boiling, very low or high pH, extended storage, and several 
freeze-thaw cycles, conditions that would normally degrade most RNAs [78]. But the most 
interesting characteristic about circulating miRNAs is that they seem to be protected from 
RNase activity, which solves the problem of possible degradation and launches them as 
the one of the top candidates for circulating biomarkers. One of the possible explanation 
for their elevated stability in circulating samples is that they circulate in exosomes [13].  As 
previously explained (Figure 2), exossome membranes are enriched in cholesterol, 
sphingomyelin, and ceramide as well as lipid raft associated proteins [79, 80]. These 
components allow exosomes to be highly stable and thus be collected from numerous 
body fluids including blood, urine, breast milk, ascites and saliva [81-86]. Consistent with 
this theory is that several authors reported differences in miRNA content when comparing 
exosomes from normal individuals with cancer patients [87-89]. Although normal cells 
within the peripheral circulation can contribute to exossome population, the primary 
source of circulating exosomes in cancer patients is the tumor [90]. Moreover, miRNA 
containing tumor-derived exosomes can affect biological processes inside of recipient 
cells and, consequently, affect the tumor microenvironment [13]. MiRNA molecules have 
also been described in exosomes shed from several tumor cell lines, including lung, 
gliobastomas and gastric cancers [87, 88, 91]. It has also been suggested that tumor 
derived exosomes could be a vehicle involved in the metastization process. Grange and 
co-workers found that CD105-positive exosomes (containing miRNAs) that were released 
by renal cell carcinoma stem cells triggered angiogenesis and the formation of a 
premetastatic nich in the lungs when injected in mice [92].  
The ubiquitous nature of exosomes in body fluids makes them ideal for use in 
diagnostic and prognostic biomarker studies. Nevertheless, little is known about the 
mechanisms in which miRNAs are selected and incorporated in exosomes and the 
biological impact of these molecules in distant sites of the body [93].  
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1.3.1. MicroRNAs as potential biomarkers in RCC 
 
The majority of the efforts made with the purpose of finding a signature of 
deregulated miRNAs in RCC has been made mainly through microarray analysis or next-
generation deep sequencing analysis, and focusing on tissue samples [94-97]. Since 
microarray analysis allows the expression analysis of hundreds of miRNAs at the same 
time, it can be an easy way to get an overall view of the overexpressed and 
underexpressed miRNAs in RCC. However, these analysis are made using a limit number 
of patients mainly due to the fact that to obtain the tissue samples invasive methods, such 
as biopsies, are required. Nevertheless, some advances have been made. Youssef and 
coworkers developed a classification system, using miRNA analysis and tissue samples, 
which can distinguish the different RCC subtypes using unique miRNAs signatures in a 
maximum of four steps. The system has a sensitivity of 97% in distinguishing normal 
RCC, 100% for clear cell RCC subtype, 97% for papillary RCC subtype and 100% 
accuracy in distinguish oncocytoma from chromophobe RCC subtype [77]. 
Regarding the circulating miRNAs in RCC, only a few have been suggested as 
potential biomarkers. MiR-378 which is known to promote cell survival and angiogenesis 
and miR-451 are upregulated in serum of RCC patients, and combined enable the 
identification of RCC serum with the sensitivity of 81% and specificity of 83% [63]. MiR-
210, which is induced by HIF-1α, is also upregulated in serum of RCC patients compared 
to healthy controls with a sensitivity of 81% and a specificity of 79% [66]. MiR-1233, which 
seems to be involved in HIF-1α activation, is also increased in the serum of RCC patients, 
with a sensitivity of 77.4% and a specificity of 37.6% [62]. 
Despite promising, these miRNAs were studied in small cohorts and need 
replication in larger samples for further validation as circulating biomarkers in RCC. Since 
the EGFR pathway is an important pathway in the molecular biology of RCC, the studying 
of some miRNAs involved in it, such as the cluster miR-221/miR-222, which is induced by 
EGFR activation, or miR-218 which is a tumor suppressor miRNA that targets EGFR, 
seem good candidates to add to some of the previous studied circulating miRNAs [98-
101]. Thus we can elucidate the role of this pathway in RCC, expand the study of 
circulating miRNAs and try to establish a miRNA signature that could act as a biomarker 
of diagnosis and/or prognosis (Figure 7).  
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Figure 7 - Representative model of VHL and EGFR pathways under 
hypoxic conditions and the proposed roles of miR-210, miR-218, miR-221, 
miR-222 and miR-1233 in RCC development.  
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2. Objectives 
 
2.1. Main objective 
The aim of the present work is the establishment of a circulating miRNA 
expression profile that could be used as biomarker of diagnosis and/or prognosis in RCC 
patients. 
 
 
2.2. Specific objectives 
 
- In a first phase it will be performed an in vitro study using a normal 
renal cell line and a renal cell carcinoma cell line to establish a circulating 
miRNA profile associated with RCC development 
 
- In a second phase it will be performed an in vivo study using plasma 
samples of healthy individuals versus RCC patients in order to validate the 
previous established miRNA expression profile 
 
- Evaluation of the overall survival in RCC patients according to the 
established miRNA expression profile 
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3. Material and Methods 
 
3.1. Phase I: In vitro study   
 
3.1.1.  Cell line characterization 
 
For this study, two renal cell lines were used: HKC-8 and FG-2. The HKC-8 cell 
line is described as proximal tubular normal renal cell line (Figure 8A). The FG-2 cell line 
is described as a metastatic RCC cell line (Figure 8B). Both cell lines were kindly provided 
by Dr. Klaas Kok from Groningem University, Netherlands. 
 
  
 
 
 
 
 
 
 
 
To confirm the tumoral phenotype of the cell lines, it was performed a 
Fluorescence in situ Hybridization (FISH) technique in both cell lines to detect the 
presence (or absence) of the VHL gene. It was used a specific probe for the centromere 
of the short arm of chromosome 3 and a specific probe for the VHL gene. As expected 
there were the same number of centromeres of chromosome 3 and respective VHL genes 
in the HKC-8 cell line (Figure 9A) and loss of the VHL gene in the FG-2 cell line (Figure 
9B). 
 
 
 
A B 
Figure 8 - (A) Microscopic image (10X) of the HKC-8 cell line. (B) Microscopic image (10X) of the FG-2 cell 
line. (Both photographs were taken using an Olympus IX51 microscope).  
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3.1.2. Cell culture 
 
 
 
3.1.2. MicroRNA extraction and cDNA synthesis 
 
Initially a cryopreserved vial of each cell line was thawed. The FG-2 cell line was 
mantained in RPMI 1640 (1X) medium (Gibco®), supplemented with 10% of FBS (Fetal 
Bovine Serum) (Gibco®), and 1% of Pen-Strep (Gibco®). The HKC-8 cell line was kept in 
DMEM/F12 medium (Gibco®), supplemented with ITS (Insuline-transferrine-selenium) 
(Sigma-Aldrich®), Pen-Strep (Gibco®), EGF (Epidermal Growth Factor) (Sigma-Aldrich®), 
Hepes buffer (Gibco®) and Hydrocortisone (Sigma-Aldrich®). Both cell lines were 
mantained in a 5% CO2 incubator at 37ºC.  
When the desired confluence was achieved (80-90%) the medium, in which the 
cells were being cultured, was collected for miRNA extraction and the cells were 
trypsinized , using 0.05 % trypsin-EDTA (1×) (Gibco®) and counted using a Neubauer 
chamber and Tripan-Blue dye (Gibco®). After counting, approximately two million cells 
were centrifuged to form a pellet for miRNA extraction and the remaining cells were kept 
in culture.  
This procedure was repeated five times for each cell line and respective medium.   
 
3.1.3. MicroRNA extraction and cDNA synthesis 
 
MicroRNA extraction (from the cells and respective medium) was performed using 
the GRS microRNA kit (Grisp®) according to manufacture instructions. After isolation, 
A B 
Figure 9 - (A) Microscopic image of the chromosome 3 centromeres and VHL genes present in the HKC-8 
cell line. (B) Microscopic image of the chromosome 3 centromeres and VHL genes present in the FG-2 cell 
line. (Red dye - chromosome 3 centromere; green dye – VHL gene). Images provided by Dr. Joana Vieira 
from the IPO-Porto Genetic Department.    
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miRNA concentration and purity were measured at 260 and 280 nm using the NanoDrop® 
ND-1000 spectrophotometer. The miRNA samples were then used as templates for cDNA 
synthesis using a Taqman®MicroRNA Reverse Transcription kit (Applied Biosystems®) 
and sequence-specific stem-loop primers for miR-210, miR-218, miR-221, miR-222, miR-
1233 and RNU-48. After protocol optimization the thermal conditions were as follows: 
16ºC for 30 min, followed by 42ºC for 60 min and 85ºC for 10 min. 
 
3.1.4. Real-time PCR relative quantification  
 
The miRNA expression was analyzed by quantitative real-time PCR. The reactions 
were carried out on a StepOneTMqPCR Real-Time PCR machine, containing 1X Master 
mix (Applied Biosystems®), with 1X probes (TaqMan® microRNA Expression Assays , 
miR-210:TM000512, miR-218:TM002094, miR-221: TM-002096, miR-222: TM-002097, 
miR-1233:TM-002768, Applied Biosystems®), cDNA sample and RNU-48 endogenous 
control (TaqMan® Gene Expression Assays, TM-001006, Applied Biosystems
®) which was 
used to normalize the results, regarding the biomarkers, since it presents a constant 
expression level. Data analysis was made using StepOneTM Sofware v2.2 (Applied 
Biosystems®) with the same baseline and threshold set for each plate, in order to generate 
threshold cycle (Ct) values for all the miRNAs in each sample. The miRNAs quantification 
was performed in duplicate and   negative control lacking cDNA was included in all 
reactions. The results were confirmed by two independent investigators. The 2-ΔΔCt 
method (Livak method) and the t’ Student test were used to evaluate the differences in the 
expression levels of the normalized miRNAs. 
This procedure was made 5 times for each cell line and respective medium. 
 
3.2. Phase II: In vivo study  
 
3.2.1. Study population  
 
The validation of the miRNA profile was made through a case-control study, 
involving a total of 100 individuals (50 RCC patients and 50 healthy individuals). All RCC 
individuals were Caucasian from the north of Portugal, with histopathologic diagnosis of 
ccRCC, admitted and treated at the Portuguese Institute of Oncology of Porto, 38 were 
male and 12 female, with ages between 60,4±12,4. 
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All the demographic and histopathologic data were collected from the clinical files 
of each patient. The staging of each patient was made according to the AJCC TNM 
classification system 2006 (6th edition) (Table II). All samples were collected after previous 
consent of each patient, according to the Helsinky declaration.  
 
  Cases (n = 50) Control Group (n =50 ) 
  n % n % 
Gender     
Male 38 76 16 30 
Female 12 24 34 68 
Age     
Average ± SD 60.4 ± 12.4  43.0 ± 15.5  
Median     
Histology      
Clear Cell 36 72   
Others 14 28   
Unknown -    
TNM Stage     
I – II 19 38   
III – IV 31 62   
Unknown - -   
T     
T1 17 34   
T2-T3 33 66   
N     
N0-N2 9 18   
Nx 41 82   
M     
M0 38 76   
M1 12 24   
Fuhrman Grade     
G1-G2 15 30   
G3-G4 32 64   
Unknown 3 6   
Microvascular invasion     
Yes 7 14   
No 34 68   
Unknown 9 18   
 
 
For the control group, 50 healthy Caucasian individuals with no history of cancer, 
were randomly recruited from the north of Portugal. All demographic data were collected 
through a written form, authorized by the ethics committee of the Portuguese Institute of 
Oncology of Porto, and signed by each individual, according to the Helsinki declaration.  
 
 
Table II – Histopathological characteristics of the population. 
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3.2.2. Sample collection and miRNA extraction, purification and 
quantification 
 
 Approximately 8 mL of peripheral blood were collected from all individuals through 
a standard method of intravenous collection with EDTA tubes. The blood tubes were 
centrifuged 5 minutes at 3000 rpm in order to separate the plasma from the blood cells.   
For miRNA isolation, we added an acid phenol-chloroform (5:1) solution (Ambion®) to the 
plasma samples, which after centrifugation at 15,000 rpm for 15 min allows the separation 
of the RNA phase. Then the miRNAs were isolated through the GRS microRNA kit 
(Grisp®), the miRNA samples were then used as template for cDNA synthesis and miRNA 
expression was analyzed by quantitative real-time PCR as previously described. 
 
 
3.2.3. Statistical Analysis 
 
Statistical analysis was also made using IBM®SPSS®Statistics software for 
Windows (Version 22.0). The 2-ΔΔCt method (Livak method) and the t’ Student test were 
used to evaluate the differences in the expression levels of the normalized miRNAs. The 
Kaplan-Meier method and Log-rank test were used to compare the miRNA expression 
profile influence in the patients overall survival. 
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Figure 10 - Variation of the intracellular and extracellular expression levels of miR-210 in HKC-8 and 
FG-2 cell lines and respective medium (Mean ± Std.Error; *P≤0.050). 
4. Results 
 
4.1. Phase I: In vitro study  
 
In figures 10 to 14, are represented the graphs relative to the intracellular and 
extracellular relative expression levels of miR-210, miR-218, miR-221, miR-222 and miR-
1233 found in both cell lines included in the in vitro study. 
According to the results obtained for miR-210, there are no differences in the 
intracellular levels of this miRNA when we compare both cell lines (P=0.324). Regarding 
miRNA excretion, when we compare the intracellular levels with the extracellular levels of 
miR-210 in the HKC-8 cell line we can´t observe any differences (P=0.744). However, 
when we compare the intracellular levels with the extracellular levels of miR-210 in the 
FG-2 cell line, we found a 2.64 fold-increase in the extracellular levels (P=0.020). In 
addition, when we compare the excretion of miR-210 in both cell lines, we observe that 
the FG-2 cell line presents a 5.94 fold-increase of miR-210 expression levels when 
compared to the HK-C8 cell line (P=0.016) (Figure 10). 
 
 
 
 
 
 
According to the results obtained for miR-218, there are no differences in the 
intracellular levels of this miRNA when we compare both cell lines (P=0.240). Regarding 
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Figure 11 - Variation of the intracellular and extracellular expression levels of miR-218 in HKC-8 and 
FG-2 cell lines and respective medium (Mean ± Std.Error; *P≤0.050). 
miRNA excretion, when we compare the intracellular expression levels with the 
extracellular expression levels of miR-218 in the HKC-8 cell line we can’t observe any 
statistical significant differences (P=0.482). Although, when we compare the intracellular 
expression levels with the extracellular expression levels of miR-218 in the FG-2 cell line, 
we can see a 302 fold-increase in the extracellular expression levels (P=0.002). However, 
if we compare the extracellular expression levels of miR-218 in both cell lines we don’t 
observe any statistical significant difference (P=0.089) (Figure 11). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
According to the results obtained for miR-221, there are no statistical significant 
differences in the intracellular levels of this miRNA when we compare both cell lines 
(P=0.213). The same happens when we compare the extracellular levels of miR-221 with 
intracellular levels in the HKC-8 cell line (P=0.674). However, when we analyze the FG-2 
cell line we can observe a trend for higher levels of miR-221 in the medium (P=0.060). 
When comparing the extracellular expression levels of miR-221, we also can´t observe 
any differences between both cell lines (P=0.934) (Figure 12). 
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Figure 13 - Variation of the intracellular and extracellular expression levels of miR-222 in HKC-8 and 
FG-2 cell lines and respective medium (Mean ± Std.Error). 
  
Figure 12 - Variation of the intracellular and extracellular expression levels of miR-221 in HKC-8 and 
FG-2 cell lines and respective medium (Mean ± Std.Error). 
 
According to the results obtained for miR-222, there are no statistical significant 
differences in the intracellular expression levels of this miRNA when we compare both cell 
lines (P=0.303). The same happens when we compare the extracellular expression levels 
of miR-222 with intracellular expression levels in the HKC-8 cell line (P=0.342) and in the 
FG-2 cell line (P=0.088). Regarding the extracellular expression levels of miR-222, we 
also can´t observe any statistical significant differences between both cell lines (P=0.759) 
(Figure 13). 
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Figure 14 - Variation of the intracellular and extracellular expression levels of miR-1233 in HKC-8 and 
FG-2 cell lines and respective medium (Mean ± Std.Error; *P≤0.050). 
According to the results obtained for miR-1233, there are no statistical significant 
differences in the intracellular levels of this miRNA when we compare both cell lines 
(P=0.589). Regarding miRNA excretion, when we compare the intracellular expression 
levels with the extracellular expression levels of miR-1233 in the HKC-8 cell line we can´t 
observe any statistical significant differences (P=0.327). However, when we compare the 
intracellular expression levels with the extracellular expression levels of miR-1233 in the 
FG-2 cell line, we can see 10.63 fold-increase in the extracellular expression levels 
(P=0.021). In addition to that, if we compare the excretion of miR-1233 in both cell lines, 
we can also observe a trend for an increase in the FG-2 cell line (P=0.054) (Figure 14). 
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Figure 15 - Relative expression of miR-210, miR-218 and miR-1233 in the plasma of RCC patients 
compared with healthy controls (Mean ± Std.Error; **P≤0.001). 
4.2. Phase II: In vivo study  
 
According to the in vitro study we observed higher extracellular expression levels 
of miR-210, miR-218 and miR-1233 in FG-2 cells, thus these miRNA profiles was 
analyzed in plasma samples of RCC patients. 
In figure 15, we can observe a significant increase in the expression levels of miR-
210, miR-218 and miR-1233 in the plasma of RCC patients, when compared to healthy 
controls (P≤0.001; P≤0.001; P≤0.001; respectively). We observed a 5.24; 27.10 and 52.34 
fold-increase in miR-210, miR-218 and miR-1233 expression levels, respectively. 
In figures 16 to 19 is represented the miRNAs relative expression levels in the 
plasma of the RCC patients and its relation with clinicopathological characteristics. 
 
 
 
 
 
 
 
Regarding tumor size, we observed that miR-210 and miR-1233 expression levels 
were increased in larger tumors (P≤0.001; P=0.007 respectively) while for miR-218 no 
significant statistical differences were observed (P=0.069). The fold-increase for miR-210 
was 7.84 and for miR-1233 was 8.05 (Figure 16). 
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Figure 16 - Relative expression of miR-210, miR-218 and miR-1233 considering tumor size (< 4cm vs 
≥ 4cm) (Mean ± Std.Error; *P≤0.050; **P≤0.001). 
Figure 17 - Relative expression of miR-210, miR-218 and miR-1233 considering the Fuhrman nuclear 
grade (Mean ± Std.Error; *P≤0.050). 
When we compare the miRNAs expression levels with the Fuhrman nuclear grade, 
we only observe a 5.13 fold-increase in miR-1233 (P=0.011), (miR-210 P=0.114 and miR-
218 P=0.216) (Figure17).  
 
 Regarding the microvascular invasion, we observe an increase in the expression 
levels of miR-210 (P=0.049) and miR-1233 (P=0.012) with fold-increase of 3.97 and 8.40, 
respectively. For miR-218, we didn’t observe any significant result (P=0.191) (Figure 18).  
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Figure 18 - Relative expression of miR-210, miR-218 and miR-1233 considering microvascular 
invasion (Mean ± Std.Error; *P≤0.050). 
Figure 19 - Relative expression of miR-210, miR-218 and miR-1233 considering the presence of 
metastatic disease (Mean ± Std.Error; *P≤0.050). 
 
 
 
 
 
 
 
 
 
 
 
 
When analyze the miRNAs expression taking into account the presence of 
metastasis, we can observe that the levels of all three miRNAs are higher in patients with 
metastatic disease when compared to patients with local disease (miR-210, P=0.005; 
miR-218, P=0.014; miR-1233, P=0.032). The fold-change for miR-210 was 4.63, for miR-
218 was 16.68 and for miR-1233 was 5.43 (Figure 19).   
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Attending the dispersion of the circulating expression levels of miR-210 and miR-
1233, we defined three miRNA expression groups among the RCC patients. Regarding 
the synergic expression of miR-210 and miR-1233, we observed a lower overall survival in 
patients who belonged to group 1 (higher expression levels of both miR-210 and miR-
1233) compared to group 2 and 3 (intermediate and lower levels of both miR-210 and 
miR-1233, respectively). Since we only observe an increase of miR-210 and miR-1233 
when considering microvascular invasion, tumor size and metastasis at the moment of 
diagnosis, we analyzed the synergic influence of both miRNAs in the overall survival of 
RCC patients (Figure 20). We observed that RCC patients that presented higher 
circulating levels of both miR-210 and miR-1233 had a lower overall survival when 
compared with patients with lower expression of these two miRNAs (Log Rank test P = 
0,036). 
 
Log Rank test (P = 0.036) 
Group 1 
Group 2/3 
Figure 20 - Overall survival by Kaplan-Meier and Log Rank test (P = 0.036) of RCC 
patients, according to the expression of miR-210 and miR-1233 in the plasma of RCC 
patients. 
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Figure 21 - Summary of miR-210 targets and their biological consequences under hypoxia. (E2F3 - E2F 
Transcription Factor 3; HOXA1 - Homeobox A1; FGFLR1 - Fibroblast Growth Factor 1; CASP8AP2 - Caspase 
Associated Protein 2; ISCU1/2 - Iron-sulfur Cluster Assembly Enzyme 1/2;  COX10 - Cytochrome C Oxydase 
10; SDHD - Succinate Dehydrogenase Complex Subunit D: EFNA3 - Ephrin-A3; PTP1B - Protein Tyrosine 
Phosphatase, non-receptor type 1; ACVR1B - activin A receptor, type IB; Tcf7l2 - Transcription Factor 7-like 2) 
(Adapted from Chan et al. 2012 [105]). 
 
5. Discussion 
 
Hypoxia is a unique environmental stress that induces global changes in a 
complex regulatory network of transcription factors and signaling pathways in order to 
coordinate cellular adaptations in metabolism, proliferation, DNA repair, and apoptosis 
[102]. As previously described, one of the early molecular events in the oncobiology o 
RCC is the loss of VHL gene which leads to an increase of HIF-α and, consequently, 
triggers and hypoxic response from the cell [46, 49]. Several lines of evidence now 
establish miRNAs as key elements in this cellular response to hypoxia [102-104]. 
HIF-responsive miR-210 is a unique miRNA that is evolutionary conserved and 
ubiquitously expressed in hypoxic cell and tissue types [105]. This miRNA is located in the 
intronic sequence that codifies AK123486 mRNA transcript that is hypoxia inducible, and 
is also flanked by, HRAS and RASSF7 genes which are also regulated by hypoxia [106, 
107]. These characteristics make this miRNA an accurate indicator of HIF-α pathway 
activation. MiR-210 has multiple direct targets and exerts its influence on a wide range of 
cellular responses known to influence normal developmental physiology, such as: 
proliferation, differentiation, mitochondrial metabolism, protein modification, nucleic acid 
binding, migration and angiogenesis (Figure 21) [108]. 
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Among miR-210 targets, EFNA3 and PTP1B are involved in angiogenesis and 
CASP8AP2 is involved in stem cell survival, which make this miRNA a potential biomarker 
for prognosis and aggressiveness [108]. Recently, studies performed by Zhao and 
coworkers showed that miR-210 was overexpressed in serum samples of patients with 
RCC compared to healthy controls, which is consistent with the results obtained in the 
present study [66]. They also described that the average serum level of miR-210 was 
significantly decreased in patients 1 week after renal resection surgery, suggesting that 
this miRNA is released from the tumor tissue into the bloodstream [66]. This result is also 
consistent with what we obtained since we observed an expression 7.84 times higher of 
miR-210 in plasma of patients with larger tumors, which supports the idea that indeed 
miR-210 could be secreted from the tumor. Valera and colleagues also observed an 
overexpression of miR-210 in tumor tissue from RCC patients and were able to associate 
increased expression levels of miR-210 with higher Fuhrman nuclear grade tumors and 
with lymph node metastasis [109]. In the present study we didn’t observe any relation with 
the plasma expression levels of miR-210 and Fuhrman nuclear grade. However, we 
observed a 4.63-fold increase in plasma expression levels of miR-210 in patients that 
presented metastasis at diagnosis. It is important to note that the present study was 
conducted in plasma samples while Valera and coworkers study was conducted in tumor 
tissue samples, which can explain our results for Fuhrman nuclear grade. 
Hypoxia stimulates the increase of numerous miRNAs, but at the same time it’s 
responsible for the downregulation of others, such as miR-218 [110]. Mathew and 
coworkers demonstrated that elevated levels of HIF-α were related to low levels of miR-
218 and that low levels of miR-218 increased the expression of multiple components of 
the EGFR pathway [110]. Moreover, results of previous functional studies of miR-218 in 
various cancers indicate that this miRNA inhibits cancer cell proliferation and invasion. 
These results strongly indicate that it functions as tumor suppressor miRNA [111-114]. 
Regarding RCC, Yamasaki and coworkers observed that miR-218 inhibits cell migration 
and invasion through targeting Caveolin-2 and that this miRNA is downregulated in RCC. 
They came to this conclusion by performing in vitro studies using cell lines and also using 
RCC tumor tissue samples [98]. However, the results obtained in the present study aren’t 
in agreement with the literature since we observed (both in vitro and in vivo) an increase 
in the extracellular expression levels of miR-218. Once again it is important to note that 
the majority of studies regarding miR-218 expression are performed using tumor tissue 
samples and in the present study we observe an increase of miR-218 in the cells medium 
and in the plasma of RCC patients but we don’t analyze its expression in tissue samples. 
Regarding the explanation to the results obtained we hypothesize that, since miR-218 is 
known as a tumor suppressor miRNA that targets EGFR and that this pathway is 
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deregulated in RCC, the excretion of miR-218 from the tumor cells could be an autocrine 
attempt from the cell to compensate EGFR pathway deregulation. Furthermore, miR-218 
also has de ability to inhibit the anti-apoptotic molecule Survivin [98]. Higher levels of 
Survivin are associated with higher RCC grade and poor prognosis [115-117]. Taking this 
into account, we can also hypothesize that the increase of the expression levels of miR-
218 function as a resistant mechanism from the cell in order to stop RCC progression.  
However, further studies are needed to validate these hypotheses. 
Recently, the miR-1233 has been described by Wulfken and colleagues as a 
potential biomarker in RCC, since an increase in its serum levels was detected in RCC 
patients when compared to healthy controls [62]. This result is consistent with we obtained 
in the present study and, to the best of our knowledge, we are the first group to relate the 
extracellular expression levels of miR-1233 with clinicalpatholocial characteristics from 
RCC patients. Our results indicate that, besides being overexpressed in the plasma of 
RCC patients, miR-1233 extracellular are also higher in patients with larger tumors, higher 
Fuhrman nuclear grade, higher microvascular invasion and presence of metastasis, which 
reinforces the potential of this miRNA in becoming a biomarker in RCC.  Regarding its 
function or what even induces its transcription, there is not much information about miR-
1233, but two of its potential targets are BLCAP (identified as a tumor suppressor gene in 
bladder cancer) and p53 [62].  
Recent evidence indicates that HIF alone is insufficient to implement the complete 
program of adaptative changes required for cell survival under hypoxic stress [102]. The 
p53 protein is a transcription factor, which is rapidly induced by cellular responses to 
hypoxia and can also work together with HIF to regulate the hypoxic response from the 
cell [118-120]. According to a model proposed by Sermeus and colleagues, under basal 
normoxic conditions, the low abundance of p53 and HIF-1α induces the expression of 
targets genes that are involved in survival. The early state of hypoxia increases the HIF 
and reduces the p53 in order to activate the hypoxic response and avoid the activation of 
pro-apoptotic signals, respectively. But if the oxygen concentration continue to decrease 
or hypoxia lasts too long, HIF-1α induces p53 increase and stabilization, leading to the 
activation of pro-apoptotic genes and, consequently, to apoptosis [118].   
Moreover, hypoxia is a primary event in RCC, due to the loss of VHL, and is as 
well-established inducer of angiogenesis and vascularization necessary for further tumor 
development. Under these conditions HIF-α expression leads to the transcription of target 
genes involved in growth of blood vessels such as VEGF, inducible nitric oxide synthase, 
fibroblast growth factor and matrix metalloproteinases [46, 49]. In response to this, p53 is 
able to limit tumor vascularization in three different ways: by increasing the production of 
antiangiogenic factors; directly inhibit HIF-α pathway by direct competition for HIF-α p300 
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co-factor and finally through the repression of genes encoding pro-angiogenic factors, 
including basic fibroblast growth factor and VEGF [121, 122] 
So, based on the previous description of p53 functions under hypoxic conditions, 
we can hypothesize that, through targeting and inhibition of p53, miR-1233 is able to 
promote a continuous state of hypoxia, cell survival and angiogenesis since it stops p53 
from doing its function.  
Considering that both miR-210 is induced by hypoxia and miR-1233 helps 
maintaining the hypoxia state, and we observed higher circulating values of both these 
miRNA in RCC patients with larger tumors, microvascular invasion and metastasis, we 
hypothesized that these two miRNAs could be potential biomarkers for aggressiveness 
and prognosis in RCC. In fact, when we performed an overall survival analyzes 
considering the expression of both miR-210 and miR-1233 we observed that the patients 
that present simultaneous higher expression of both these miRNAs died early, which 
sustains our hypothesis.  
Thus, we propose that these patients, with high expression levels of both miR-210 
and miR-1233, will present a higher stimulus to cell growth, angiogenesis, stem cell 
survival and apoptosis inhibition, which translates in a poor overall survival (Figure 22).  
 
 
Figure 22 - Proposed model of miR-210 and miR-1233 role during RCC development, according to the results 
obtained in the present study. 
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6. Conclusions and Future Perspectives 
 
The reality of the non-existence of a standard screening test for the early detection 
and follow-up in RCC has been haunting the field of Oncology for the past years once 
RCC is the most lethal urologic neoplasia.  
The hypothesis of exosome-dependent signaling between cells has been 
revolutionizing molecular biology and giving space for reformulating the idea of tumor 
microenvironment and the mechanism by which metastization occurs. Exosomes are 
small microvesicles that present high stability in several body fluids and can be released 
from a wide range of cell, including cancer cells. They can be uptaken by neighboring 
cells and are capable of inducing pathways involved in cancer initiation and progression. 
Among the cargo that can be transported through exosomes we can find miRNAs. 
MiRNAs are small non-coding RNAs responsible for the regulation of numerous genes at 
a post-transcriptional level. In the last few years they have been widely studied in cancer 
since they can act as oncomiRNAs (if they inhibit tumor suppressor genes) or tumor 
suppressor miRNAs (if they inhibit oncogenes). 
Recently, expression profiling has emerged as a powerful approach to identify the 
molecular mechanism underlying carcinogenesis and to predict clinical outcomes, helping 
to identify new biomarkers of aggressiveness and prognosis. The analysis of miRNAs 
expression patterns offers an opportunity for the identification of several tumors, since 
some of these molecules appear to be differentially expressed in normal versus cancer 
tissues and in different phases of cancer development. 
In the present study we found that miR-210 and miR-1233 (classified as 
oncomiRNAs) presented high expression levels in the plasma samples of RCC patients 
and that those higher levels are associated to higher tumor size, higher Fuhrman nuclear 
grade, higher microvascular invasion and metastasis at the time of diagnosis, which made 
them eligible for potential biomarkers of prognostic and aggressiveness in RCC. To 
support our hypothesis, we observed that patients with higher expression levels of these 
miRNAs in plasma presented a poor overall survival. 
However, there are some limitations in this study. We only used circulating 
samples from RCC patients in order to study potential non-invasive biomarkers but in the 
future it would be useful to study the corresponding tumor samples in order to study the 
relationship between the intercellular/extracellular levels of these miRNAs, as we did for 
the in vitro phase of the study. Future studies must include a higher number of miRNAs. 
We started with a panel of five miRNAs, but only three passed the in vitro phase of the 
study and in the end only two were related with RCC patients overall survival. Thus, as 
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future perspectives it would be interesting to: replicate this study in a larger number of 
RCC patients to validate the results obtained in this study; collect plasma samples before 
and after surgery in order to validate the hypothesis that the miRNAs are released from 
the tumor to the bloodstream; collect tumor samples to compare with the plasma samples 
and search for more deregulated miRNAs in RCC in order to improve the established 
miRNA profile. 
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Renal cell carcinoma development and miRNAs: 
a possible link to the EGFR pathway
Epidemiology of renal cell carcinoma
Renal cell carcinoma (RCC) is the most common 
solid cancer of the adult kidney, accounting for 
approximately 90% of kidney neoplasms and 3% 
of all adult malignancies [1,2]. According to the 
European Association of Urology, there is a 1.5:1 
predominance of new cases diagnosed in men 
over women, with a peak of incidence occurring 
between the age of 60 and 70 years [2]. Worldwide 
mortality, as a result of RCC, currently exceeds 
100,000 patients each year, with the incidence 
and mortality rate increasing by 2–3% per decade 
[3]. According to the 2004 WHO classification, 
the three most prevalent kidney cancer histologi-
cal subtypes are clear cell RCC, papillary RCC 
and chromophobe RCC (with a prevalence of 70, 
10 and 5%, respectively) [4].
Actually, the majority of RCC cases are 
detected accidentally as a consequence of diag-
nostic tests (computed tomography, MRI and so 
on) owing to symptoms that are not specifically 
related to the disease [1,5]. This reality and the 
nonexistence of a standard screening test, con-
tributes to the fact that one-third of patients are 
diagnosed with local invasive disease or meta-
static disease [6]. Although surgical resection 
remains the best curative therapy approach for 
RCC, 20–40% of patients will develop recurring 
disease after surgical nephrectomy [7], due to the 
inexistence of adjuvant therapy in clinical rou-
tine [4]. RCC is both chemotherapy and radio-
therapy resistant [8]. Another issue related to this 
type of cancer is the absence of biomarkers for 
the early detection and follow-up of the disease, 
which complicate the early diagnosis and makes 
it a challenge for the field of oncology [8].
Actually, despite intensive efforts, the mecha-
nisms involved in RCC development and pro-
gression remain under study. One of the signal-
ing pathways involved in the pathophysiology 
of RCC is the von Hippel–Lindau (VHL) path-
way [9–13]. In normoxic conditions, the protein 
encoded by the VHL gene serves as a recognition 
site for the regulatory subunits of HIF, target-
ing them for proteosome degradation (Figure 1A). 
One of the early molecular events of RCC is the 
loss of pVHL (a consequence of the loss of the 
short arm of chromosome 3), which stops the 
degradation of HIF and leads to its accumula-
tion in the cytoplasm and further migration to 
the nucleus where it binds to hypoxia-related 
genes, leading to a hypoxic response from the 
cell. Once activated, these genes are involved 
in pathways responsible for the development of 
blood vessels, proliferation, glucose metabolism, 
pH regulation and metastatic disease (Figure 1B) 
[14–16]. One of the activated genes is TGF-a, 
which is involved in the induction of cellular 
proliferation by activating the EGF receptor 
(EGFR) [17]. This receptor is a membrane gly-
coprotein that belongs to the ErbB family of 
tyrosine kinase receptors [18]. The EGFR acti-
vates several signaling pathways, including the 
MAPK/ERK and PI3K/AKT pathways [19]. 
These pathways can modulate genetic tran-
scription, stimulating cellular proliferation, 
migration, invasion, angiogenesis and apoptosis 
inhibition (Figure 1C) [20].
Renal cell carcinoma (RCC) is the most common solid cancer of the adult kidney and the majority of RCC 
cases are detected accidentally. This reality and the nonexistence of a standard screening test contribute 
to the fact that one third of patients are diagnosed with local invasive disease or metastatic disease. 
miRNAs are a family of small ncRNAs that regulate gene expression and have been identified as key 
regulators in many biological processes including cell development, differentiation, apoptosis and 
proliferation. The EGF receptor signaling pathway is usually deregulated in cancer and it is suggested to 
have an important role in RCC. Further studies are needed to characterize deregulation of this pathway 
during RCC development. In this review we highlight some potential miRNAs that could be involved in 
the modulation of the EGF receptor pathway and consequently in RCC development.
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EGFR overexpression is found in approxi-
mately 30% of primary tumors and has been 
associated with advanced disease, poor progno-
sis, overall survival and therapy response [21,22]. 
The VHL is also responsible for EGFR turnover 
and further degradation in the proteosome, thus 
during the RCC development these processes 
could be compromised, leading to an increase 
of the EGFR [23]. Zhou and coworkers described 
EGFR half-life as approximately 1 h in 786-
VHL cells but approximately 3 h in 786-mock 
cells and that both the phospho-AKT and the 
phospho-ERK signals lasted longer in 786-mock 
cells than in 786-VHL cells when stimulated 
with EGF [23]. If we relate the increase in EGFR 
half-life with the increase of TGF-a production, 
it becomes clear the relevance of the study of 
this pathway in RCC. It has also been described 
that hypoxia upregulates EGFR and prolongs 
its activation through its retention in endocytic 
trafficking [24]. Recently, Shen and colleagues 
demonstrated that EGFR is upregulated during 
tumor progression and specifically enriched in 
hypoxic tumor areas. They also described EGFR 
suppression of miRNA maturation through 
AGO2-Y393 phosphorylation under hypoxic 
conditions [25].
In recent years, the increasing knowledge 
of the pathways involved in RCC has allowed 
for the development of new targeted therapies. 
The identification of the influence of the VHL 
gene in RCC led to the development of targeted 
therapies such as sunitinib and sorafenib (tyro-
sine kinase domain inhibitors), as well as pazo-
panib (angiogenisis inhibitor); these therapies 
are directed towards this molecular pathway 
[15,26]. However a subset of patients (~25%) 
do not seem to experience any clinical benefit 
from targeted therapy, while in the majority 
of cases, patients respond to therapy initially 
but go on to experience disease progression 
[27]. Usually resistance to the targeted agents 
has been shown to develop after a median of 
5–11 months of treatment and a small subset of 
patients do not experience any clinical benefit 
from the targeted therapy [28]. These ‘failures’ 
of targeted therapies show us the necessity of 
further investigation into the molecular path-
ways involved in RCC in order to improve our 
understanding about molecular events in this 
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Figure 1. signaling pathways involved in renal cell carcinoma pathophysiology. (A) pVHL pathway under normoxic conditions: 
pVHL targets HIF-a for degradation in the proteosome. (B) pVHL pathway under hypoxic conditions: the loss of pVHL leads to the 
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type of cancer and to allow for the development 
of new effective targets and therapies.
mirNAs & cancer
miRNAs (also known as miRs) are a family of 
small ncRNAs (19–25 nucleotides in length) that 
regulate gene expression by sequence- selective 
targeting of mRNAs, leading to degradation or 
blockade of mRNA at the post-transcriptional 
level, depending on the degree of complemen-
tarity between miRNAs and the target mRNA 
sequence [29,30].
For the majority of miRNAs, the primary 
transcripts are generated in the nucleus [31]. 
Following transcription, the pri-miRNA is 
processed by DROSHA and its binding part-
ner DGCR8 (also known as Pasha), creating a 
pre-miRNA [32]. The pre-miRNAs are exported 
to the cytoplasm by the nuclear export protein 
XPO5, where they are further processed by 
DICER, leading to the production of mature 
approximately 22 nucleotide double-stranded 
molecules [33]. The mature miRNA enters the 
miRISC complex where it is further processed, 
leaving a single-stranded functional miRNA. 
This single-stranded miRNA then induces 
post-transcriptional gene silencing by guiding 
the miRISC complex to target mRNAs. Target 
recognition occurs mainly by incomplete base 
pairing complementarity between the miRNA 
and the target mRNA, resulting in mismatches 
that, in turn, lead to target gene silencing, which 
can occur via translational repression and/or 
mRNA degradation (Figure 2) [33,34].
miRNA expression is dynamic, so may be 
altered within the same cell. This variability 
makes miRNAs potent modulators of cellu-
lar behavior, since several miRNAs can target 
the same gene and one single miRNA can tar-
get multiple genes [35]. Hence, miRNAs have 
been identified as key regulators in many bio-
logical processes including cell development, 
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Figure 2. mirNA biogenesis and processing mechanism.
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differentiation, apoptosis and proliferation [36]. 
miRNAs deregulation can modulate the renal 
cell microenvironment, which can impact on 
cancer development. We previously observed 
that slight differences in microenvironment, 
owing to functional SNPs, can be associated 
with RCC development [37].
As a single miRNA may target up to several 
hundred mRNAs, aberrant miRNA expression 
may affect a multitude of transcripts and pro-
foundly influence cancer-related signaling path-
ways [31]. Many miRNAs have been identified 
to act as oncogenes, tumor suppressors or even 
modulators of cancer stem cells and metastasis 
formation [38]. OncomiRs are known to down-
regulate tumor suppressor genes, and have been 
reported to be overexpressed in multiple miRNA 
expression-profiling studies. On the other hand, 
tumor suppressor miRNAs are responsible for 
downregulating oncogenes, and are mostly 
underexpressed in cancer [33]. Duns and cowork-
ers reported that the miR-200 family, a fam-
ily of tumor suppressor miRNAs known to be 
implicated in the epithelial-to-mesenchymal 
transition process, are deregulated in clear cell 
(ccRCC) [39].
miRNAs represent attractive drug targets 
since they regulate the expression of several cel-
lular proteins and are differentially expressed in 
malignant cells when compared to normal cells.
mirNA expression modulation 
during rCC development
The EGFR–PI3K–AKT pathway is frequently 
overexpressed in ccRCC [40]. In this section 
we will focus in some miRNAs that have been 
described as frequently deregulated in RCC 
and relate them to the EGFR pathway. Since 
the majority of deregulated miRNAs involved 
in this pathway are upregulated in RCC, we 
will focus on these miRNAs. To the best of 
our knowledge no reports have been published 
relating downregulated miRNAs in RCC to the 
EGFR pathway.
miR-21 is described in the literature as pre-
senting an oncogene role in cancer development 
[41–43]. In a variety of cancer cell lines, over-
expression of miR-21 could increase cell prolifer-
ation, migration, invasion and survival, while its 
suppression could induce apoptosis and repress 
cell proliferation and invasion capacity (TABle 1) 
[44]. In a large-scale meta-ana lysis of miRNA 
expression using 540 human samples of six types 
of solid tumors, miR-21 was the only miRNA 
upregulated in all the tumors, therefore over-
expression of miR-21 may be a general feature 
of carcinoma and be used as a biomarker [44]. 
miR-21 transcription can be induced by AP1, 
NF-kB and RAS/ERK signaling pathways and 
this miRNA has multiple targets involved in dif-
ferent cellular processes [45]. Some of the targets 
of miR-21 include p53 and Cdc25A, which are 
related to cell cycle control; TIMP1, TIMP3 
and RECK, which are related to invasion; and 
PTEN, PDCD4 and FasL, which modulate 
apoptosis [45]. Regarding RCC, Zhang and col-
leagues demonstrated that aberrantly expressed 
miR-21 regulates the TCF21–KISS1-associated 
RCC invasion pathway, and this miRNA sig-
nature could offer a novel potential therapeutic 
strategy for RCC [41].
Recently, Liu and coworkers demonstrated 
that miR-21 could induce tumor angiogenesis 
through targeting of PTEN, leading to the 
Table 1. Chromosome location, predicted target genes and functional 
consequences of mir-21, mir-155, mir-210, mir-221, mir-222 and mir-1233 in the 
context of renal cell carcinoma and EGFr pathway.
mirNA Location Predicted genes Consequence ref.
miR-21 17q23.1 p53, Cdc25A, TIMP1, TIMP3, RECK, 
PTEN, PDC4 and FasL
↑ proliferation
↑ invasion
↓ apoptosis
[45,46]
miR-155 21q21.3 HIF-1a ↑ proliferation
↓ apoptosis
[48]
miR-210 11p15.5 EFNA3, PTP1B and CASP8AP2 ↑ stem cell survival
↑ invasion
[52]
miR-221/222 Xp11.3 PTEN, TIMP3 and TRPS1 ↑ invasion
↑ proliferation
↓ apoptosis
[19,54–56]
miR-1233 15q14 BLCAP and p53 ↑ proliferation [58]
↑: Increase; ↓: Decrease. 
Data taken from [101].
www.futuremedicine.com 1797future science group
Renal cell carcinoma development & miRNAs: a possible link to the EGFR pathway ReviewReview Dias, Teixeira, Santos et al.
activation of AKT and ERK1/2 signaling path-
ways, and thereby enhancing HIF-1a and VEGF 
expression [46]. Cells treated with an antisense-
miR-21 showed a decreased expression of EGFR, 
activated AKT, cyclin D and Bcl-2 leading to cell 
proliferation and differentiation inhibition [47].
Another miRNA involved in hypoxia 
response is miR-155. This miRNA is induced 
by hypoxia and plays a role as a component 
of a network of negative feedback loops that 
controls HIF-1a translation [48]. It has also 
been reported that miR-155 is involved in the 
downregulation of many tumor suppressor 
genes that repress PI3K related pathways [49]. 
As a consequence, pathways involving EGFR 
will be constantly activated. miR-155 is signifi-
cantly upregulated in ccRCC compared with 
normal cells and high expression levels of miR-
155 were correlated with increased tumor size 
[49,50]. On the other hand Shinmei and cowork-
ers also described a suppression of miR-155 
expression in patients with stage III and stage 
IV ccRCC and correlated it with a poor prog-
nosis [49]. These data suggest that miR-155 
may have different roles during ccRCC pro-
gression: initially its overexpression is related 
to an increase in tumor size and, when the 
tumor reaches stages III and IV, a suppression 
of miR-155 occurs and is related to a poorer 
prognosis for the patient. Although more stud-
ies are needed to explain this transition, this 
phenomenon of over- and under-expression of 
miR-155 may be explained by its involvement 
in the network of negative feedback loops that 
control HIF-1a translation.
miR-210, is another miRNA that is regulated 
by HIF-1a. HIF-1a accumulation in the cell is 
a key event in RCC owing to VHL mutation, 
therefore we expect to find higher levels of this 
miRNA in RCC patients [51]. As explained ear-
lier, HIF-1a accumulation also results in the 
transcription of TGF-a, which in turn will 
stimulate the EGFR pathway. So, we can expect 
that an overexpression of miR-210 and TGF-a 
could be related since they are both regulated 
by HIF-1a (Figure 3). Among miR-210 targets, 
EFNA3 and PTP1B are involved in angiogen-
esis and CASP8AP2 is involved in stem cell sur-
vival [52]. Recently, studies performed by Zhao 
and coworkers showed that miR-210 was over-
expressed in serum samples (n = 68) of patients 
with RCC compared with healthy controls 
(n = 32; with an area under the curve of 0.874, 
a sensitivity of 81% and a specificity of 79.4%) 
[53]. They also described that the average serum 
level of miR-210 was significantly decreased 
in patients 1 week after resection surgery 
(p < 0.001), suggesting that this miR is released 
from the tumor tissue into the bloodstream [53]. 
According to a report by Valera and coworkers, 
an overexpression of miR-210 in RCC patients 
was observed and increased expression levels of 
miR-210 are associated with higher Fuhrman 
nuclear grade tumors and tumors with lymph 
node metastasis [51].
During RCC development, TGF-a transcrip-
tional activation may result in cellular prolifera-
tion induction as a consequence of PI3K/AKT 
pathway activation. The PI3K/AKT pathway is 
correlated with apoptosis resistance, increased 
proliferation, cellular migration and survival 
signaling (normally dependent on growth fac-
tors) [54]. This pathway activation can lead to 
an increase in miR-221 and miR-222 expression 
EGFR
PI3K RAS
PDK1,2
AKT
RAF
MEK
ERK
PTEN
DNA damage/hypoxia
mTOR
Renal cell carcinoma
Inhibition of apoptosis, proliferation, 
migration and angiogenesis 
miR-155
miR-1233
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Figure 3. Link between the VHL and EGFr pathways, the mirNAs involved 
and their target genes.
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levels. These two miRNAs can target the 
3 -´UTR sequence of PTEN and TIMP3 lead-
ing to their degradation [54,55]. The upregulation 
of miR-221/222 leads to the downregulation 
of PTEN and consequent activation of AKT 
(Figure 3) [19]. Works performed by Zhang and 
coworkers described that the activation of AKT 
by the downregulation of PTEN is related to the 
gain of radioresistance and when the two miR-
NAs are knocked down, the expression of PTEN 
is re-established, resulting in an enhancement in 
radiation-induced apoptosis in tumor cells [54]. 
miR-221/222 are also involved in the metastatic 
process. Their overexpression is related to cel-
lular invasion by directly targeting TIMP3, an 
inhibitor of metalloproteinases, and by repress-
ing transcriptional factors, such as the TRPS1 
[54,56]. The repression of this factor causes an 
increase in the levels of the ZEB2, which pro-
motes a crucial step in the epithelial-to-mesen-
chymal transition, essential for the development 
of metastasis [56,57]. Recently, the miR-1233 has 
been described by Wulfken and colleagues as a 
potential biomarker in RCC, since an increase 
in its serum levels was detected in RCC patients 
(n = 30) when compared with healthy controls 
(n = 33; sensitivity 77%, specificity 37.6%, 
area under the curve 0.588) [58]. Regarding its 
function, there is not much information about 
miR-1233, but two of its potential targets are 
BLCAP (identified as a tumor suppressor gene 
in bladder cancer) and p53, so we can hypoth-
esize that it is related to the regulation of tumor 
suppressor genes [58].
Since p53 can target and inhibit HIF-1a, it 
is possible that miR-1233 overexpression results 
in the inhibition or suppression of p53 which in 
turn will result in HIF-1a activation [59,60]. This 
will lead to TGF-a transcription and EGFR 
pathway activation (Figure 3).
mirNAs as potential biomarkers for 
diagnosis & prognosis in rCC
Owing to RCC characteristics, new and precise 
biomarkers are needed for early detection and 
for follow-up regarding disease progression. The 
characterization of these new biomarkers could 
be an interesting approach for the identification 
of novel therapeutic targets and could accel-
erate the development of new drugs for RCC 
treatment.
n miRNAs as biomarkers in body fluids
Besides the fact that miRNAs are differentially 
expressed in normal cells versus cancer cells, 
miRNA expression signatures in the blood, 
serum and plasma are similar in men and 
women, as well in individuals of different ages 
[58]. On the other hand, levels of miRNAs in cir-
culating samples are reproducible and consistent 
among individuals of the same species and spe-
cific expression patterns of serum miRNAs have 
already been identified for pregnancy, diabetes 
and different cancers, thus providing evidence 
that serum miRNAs contain fingerprints dis-
tinctive of certain human conditions [19]. These 
characteristics make them good candidates for 
cancer-specific biomarkers.
Regarding RCC, some miRNAs have been 
suggested as serum biomarkers: miR-378, as it is 
known to promote cell survival and angio genisis 
and is upregulated in the serum from patients 
with RCC; whereas miR-145, which sensitizes 
cells to glucose deprivation, is downregulated in 
serum from patients with RCC [61]. Recently, our 
group observed that miR-222 expression levels 
are increased in RCC patients compared with 
healthy individuals, and the higher expression 
levels of miR-222 are also associated with a lower 
overall survival [62] [Teixeira AL, Gomes M, Medeiros 
R. Circulating miR-221/222 in renal cell carcinoma: a 
new potential biomarkers for diagnosis and prognosis 
in Portuguese population (2012), Submitted]. Despite 
the concept of using miRNAs for cancer diagno-
sis and prognosis seeming very promising, RCC-
specific biomarkers have not yet been identified 
and more studies are needed to establish a solid 
miRNA signature for RCC diagnosis [63]. 
n miRNAs as biomarkers in tissue 
samples
Another example of the utility of miRNAs as 
potential biomarkers for diagnosis is a study per-
formed by Jung and coworkers in which they iden-
tified a robust signature to define ccRCC, with 
five significantly overexpressed and six signifi-
cantly downregulated miRNAs in cancer tissue 
samples. A combination of upregulated miR-155 
and downregulated miR-141 is found to result in 
a 97% overall correct classification of the matched 
malignant and nonmalignant tissue samples [64]. 
In stage II colorectal cancer miRNA expression 
profiles were capable of predicting recurrence 
rates with an accuracy of >80%, suggesting that 
miRNA profiling can also be used to determine 
a tumor’s aggressiveness [65].
In addition, miRNA expression patterns can 
help distinguish tumor histopathological sub-
types. Youssef and coworkers developed a clas-
sification system, using microarray ana lysis that 
can distinguish the different RCC subtypes using 
unique miRNA signatures in a maximum of four 
www.futuremedicine.com 1799future science group
Renal cell carcinoma development & miRNAs: a possible link to the EGFR pathway ReviewReview Dias, Teixeira, Santos et al.
steps. The system has a sensitivity of 97% in dis-
tinguishing normal RCC, 100% for clear cell 
RCC subtype, 97% for papillary RCC subtype, 
and 100% accuracy in distinguishing oncocytoma 
from chromophobe RCC subtype [66].
Taken together, these data suggest that cir-
culating miRNAs have the potential to become 
powerful and sensitive biomarkers, which can 
be easily detectable in noninvasive assays that 
might overtake the antibody-related drawbacks 
of proteomics approaches and could help in the 
diagnosis and prognosis of several types of cancer, 
namely RCC.
mirNAs as potential tools for 
targeted therapy
In general, technological advances are enabling 
the synthesis of pre- or anti-RNA molecules 
within carrier vehicles that can be administered 
topically or systematically to induce generalized 
cell targeting. If the targeted event is cancer 
specific, then the effects should be harmless to 
normal cells and antineoplastic cells (Figure 4) [35]. 
There are four types of miRNA delivery strategies 
to restore miRNA levels in cancer: antagomirs 
and locked nucleic acids (which do not need a car-
rier to enter the cell); viral carriers such as lentivi-
ruses, adeno viruses and adeno-associated viruses; 
nonviral carriers such as cationic or neutral lipo-
somes, polyethyleneimines and atelo collagen; and 
single chain or peptide-targeted nanoparticles [33].
Several authors, using intravenous injec-
tions of cholesterol-conjugated single-stranded 
antagomirs (stabilized by 2’O-methylations) 
demonstrated that it is possible to inhibit the 
miRNAs overexpression linked to tumorigenic 
processes [31]. For example, the inhibition of 
miR-10b in mice transplanted with a high met-
astatic breast cancer cell line using this method 
resulted in a robust inhibition of metastasis to 
Nucleus
5´ 3´
Mature miRNA
5´ 3´5´3´
Cytoplasm
Inhibit miRNA
function
or
Nanoparticles Liposomes AntagomirVirus
Restore miRNA
levels
Figure 4. Proposed strategies for mirNA delivery in targeted therapies. Once inside the cell, 
the miRNAs can serve as antagomirs and inhibit the function of another miRNA, or they can restore 
the levels of miRNAs that were suppressed or deleted and recover their function.
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the lung [67]. The same antineoplasic effects 
were reported by Park and coworkers. When 
they inhibited miR-221 using a xenograft 
model for hepato cellular carcinoma there was 
a reduction in tumor cell proliferation accom-
panied by an elevated level of apoptosis [68]. 
Another way to inhibit oncogenic miRNAs is 
through the reintroduction of tumor-suppres-
sive miRNAs [33]. This is mainly carried out 
with the use of lipid-vesicles or by viral delivery 
of miRNAs. An example of such  an application 
is the reintroduction of miR-26a into a mouse 
model of hepatocellular carcinoma, where the 
systemic delivery of miR-26a expressed from an 
Executive summary
Epidemiology of renal cell carcinoma
  Renal cell carcinoma (RCC) is the most common solid cancer of the adult kidney, accounting for approximately 90% of kidney 
neoplasms and 3% of all adult malignancies.
  The nonexistence of a standard screening test contributes to the fact that one-third of the patients are diagnosed with local invasive 
disease or metastatic disease.
  One of the early molecular events of RCC is the loss of pVHL, which stops the degradation of HIF and leads to its accumulation in the 
cytoplasm and further migration to the nucleus where it binds to hypoxia related genes. One of those genes is TGF-a.
  TGF-a is involved in the induction of cellular proliferation, migration, invasion and apoptosis by activating the EGF receptor (EGFR) 
signaling pathway.
miRNAs & cancer
  miRNAs are a family of small ncRNAs that regulate gene expression by sequence-selective targeting of mRNAs, leading to degradation 
or blockade of mRNA at the post-transcriptional level.
  miRNAs have been identified as key regulators in many biological processes including cell development, differentiation, apoptosis and 
proliferation.
  Many miRNAs have been identified to act as oncogenes, tumor suppressors or even modulators of cancer stem cells and metastasis 
formation.
miRNA expression modulation during RCC development
  miR-21 overexpression can increase cell proliferation, migration, invasion and survival. Aberrantly expressed miR-21 regulates the 
TCF21–KISS1-associated RCC invasion pathway. Cells treated with an antisense miR-21 showed a decreased expression of EGFR, 
activated AKT, cyclin D and Bcl-2 leading to cell proliferation and differentiation inhibition.
  miR-155 may have different roles during clear cell RCC progression: initially its overexpression is related to an increase in tumor size and 
later, when the tumor reaches stages III and IV, a suppression of miR-155 occurs and it is related to a poorer prognosis for the patient. 
This miRNA is induced by hypoxia and plays a role as a component of a network of negative feedback loops that control HIF-1a 
translation.
  miR-210 is overexpressed in serum samples of patients with RCC compared with healthy controls and the average serum level of 
miR-210 was significantly decreased in patients 1 week after resection surgery, suggesting that this miRNA is released from the tumor 
tissue into the bloodstream. This miRNA is regulated by HIF-1a, so if we have high levels of HIF-1a we can expect higher levels of 
miR-210.
  The PI3K/AKT pathway is correlated with apoptosis resistance, increased proliferation, cellular migration and survival signaling. This 
pathway is activated by the EGFR and leads to the increase of miR-221 and miR-222 expression levels. These miRNAs are associated 
with radioresistance and epithelial-to-mesenchymal transition. Higher expression levels of miR-221 are also associated with a lower 
overall survival in patients with RCC.
  miR-1233 has been described as a potential biomarker in RCC, since it was detected an increase of its levels in the serum of RCC 
patients when compared with healthy controls has been observed. It is proposed that miR-1233 overexpression results in the inhibition 
or suppression of p53, which in turn will result in HIF-1a activation.
miRNAs as potential biofluid markers for diagnosis & prognosis
  The levels of miRNAs in circulating samples are reproducible and consistent among individuals of the same species, and specific 
expression patterns of serum miRNAs have already been identified as fingerprints of distinctive human conditions, one of them being 
cancer.
  miRNAs can be used as potential biomarkers for diagnosis.
  miRNA expression profiles are capable of predicting recurrence rates with accuracy.
  miRNA expression patterns can help distinguish tumor histopathological subtypes.
miRNAs as potential tools for targeted therapy
  There are four types of miRNA delivery strategies to restore miRNA levels in cancer: antagomirs and locked nucleic acids, viral carriers, 
nonviral carriers and single chain or peptide-targeted nanoparticles.
  Although targeting miRNAs provides an efficient way to modulate gene expression, the efficacy and safety of miRNA-derived drugs 
must be carefully assessed and will depend on tumor cells type and context.
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